Ziextenzo, also known by its generic name pegfilgrastim-bmez, is a biosimilar to Neulasta (pegfilgrastim), designed to help reduce the chance of infection in patients with certain types of cancer. It is specifically used in individuals who are receiving chemotherapy that is known to cause a significant decrease in white blood cells, increasing the risk of infection. Ziextenzo works by stimulating the bone marrow to produce more neutrophils, a type of white blood cell important for fighting infections. Administered as an injection, it is part of a class of drugs known as colony-stimulating factors. Ziextenzo offers a supportive care option to improve the outcomes for patients undergoing chemotherapy by enhancing their immune system's ability to combat infections.